iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 326,400 shares, a drop of 8.3% from the August 15th total of 355,900 shares. Currently, 3.2% of the shares of the company are sold short. Based on an average trading volume of 1,970,000 shares, the days-to-cover ratio is presently 0.2 days.
iSpecimen Stock Up 6.2 %
Shares of ISPC traded up $0.32 during mid-day trading on Wednesday, hitting $5.52. 1,300,880 shares of the company’s stock were exchanged, compared to its average volume of 118,110. The firm has a market cap of $72.17 million, a price-to-earnings ratio of -4.38 and a beta of 1.60. The stock’s 50-day simple moving average is $0.46 and its 200-day simple moving average is $0.36. iSpecimen has a 52 week low of $3.41 and a 52 week high of $15.38.
iSpecimen (NASDAQ:ISPC – Get Free Report) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.09. The firm had revenue of $2.86 million during the quarter. iSpecimen had a negative return on equity of 115.36% and a negative net margin of 97.03%.
About iSpecimen
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
Read More
- Five stocks we like better than iSpecimen
- The Basics of Support and Resistance
- This Is the Top Large-Cap Stock Insiders Are Buying
- How to Invest in Biotech Stocks
- Capitalize on Micron’s 24% Drop—Wall Street Eyes Major Upside
- Profitably Trade Stocks at 52-Week Highs
- Stocks to Take Advantage of Rising Gold Prices
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.